Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy

The approved antisense oligonucleotide nusinersen demonstrated convincing clinical results in patients with 5q-linked spinal muscular atrophy (SMA) but predictive biomarkers are lacking to date.

Saved in:

Bibliographic Details
Main Authors:	Keßler, Tobias (Author) , Latzer, Pauline (Author) , Schmid, Dominic (Author) , Warnken, Uwe (Author) , Saffari, Afshin (Author) , Ziegler, Andreas (Author) , Hayes, Jennifer (Author) , Möhlenbruch, Markus Alfred (Author) , Ulfert, Christian (Author) , Herweh, Christian (Author) , Wildemann, Brigitte (Author) , Wick, Wolfgang (Author) , Weiler, Markus (Author)
Format:	Article (Journal)
Language:	English
Published:	2020
In:	Journal of neurochemistry Year: 2020, Volume: 153, Issue: 5, Pages: 650-661
ISSN:	1471-4159
DOI:	10.1111/jnc.14953
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1111/jnc.14953 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/10.1111/jnc.14953
Author Notes:	Tobias Kessler, Pauline Latzer, Dominic Schmid, Uwe Warnken, Afshin Saffari, Andreas Ziegler, Jennifer Kollmer, Markus Möhlenbruch, Christian Ulfert, Christian Herweh, Brigitte Wildemann, Wolfgang Wick, Markus Weiler

Description
Summary:	The approved antisense oligonucleotide nusinersen demonstrated convincing clinical results in patients with 5q-linked spinal muscular atrophy (SMA) but predictive biomarkers are lacking to date.
Item Description:	First published: 06 January 2020 Gesehen am 12.01.2022
Physical Description:	Online Resource
ISSN:	1471-4159
DOI:	10.1111/jnc.14953